by John A. Jenkins | Feb 4, 2026 | FDA, FOIA, Litigation, Pharmaceuticals, Stock Market
FOIAengine: Media Requests Were Warnings, Months Before Bad News Hit In the early days of the Covid pandemic, there was big money on the line as pharmaceutical companies scrambled to produce vaccines. The world needed a miracle. The companies that could deliver it...
by John A. Jenkins | Jan 14, 2026 | FDA, FOIA, News Media, Pharmaceuticals
FOIAengine: Warning Letters and Inspection Reports in the Spotlight Freedom of Information Act requests filed with the Food and Drug Administration by hedge funds last month revealed big financial players closely eyeing warning letters, enforcement documents, and...
by John A. Jenkins | Jan 8, 2026 | FDA, FOIA, News Media, Pharmaceuticals
FOIAengine: Growing Scrutiny of Drug Safety and Enforcement As GLP-1 weight-loss drugs surge in popularity, major news organizations are pressing the Food and Drug Administration for internal records that reveal what regulators knew about reports of dangers...
by John A. Jenkins | Dec 10, 2025 | FDA, FOIA, News Media, Pharmaceuticals
FOIAengine: The Investigative Outlet Gets Active at the FDA Capitol Forum may be one of the more under-the-radar journalistic enterprises in Washington, but recently it was easily the most active when it came to filing FOIA requests with the Food and Drug...
by Randy E. Miller | Aug 21, 2025 | FOIA, Pharmaceuticals, Politics
FOIAengine: Maker of Elevidys Targeted by 91 FOIA Requests in 19 Months As biotech firm Sarepta Therapeutics (NASD: SRPT) battles patient deaths, regulatory action, and a cratering stock price, its dealings with the Food and Drug Administration are being monitored...
by Randy E. Miller | Apr 23, 2025 | FDA, FOIA, Hedge Funds, Pharmaceuticals
FOIAengine: Questions Seek Adverse Reports about Carvykti According to a new PoliScio Analytics analysis of early 2025 Freedom of Information Act requests, investment firm Point72 has launched a significant FOIA-driven investigation into Johnson &...
